Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value?

Why Ziihera’s Phase 3 data matters for Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) is back in focus after fresh Phase 3 HERIZON-GEA-01 results for Ziihera and an FDA approval in HER2-positive gastroesophageal adenocarcinoma earlier in August 2026.

The update showed statistically significant and clinically meaningful overall survival benefits for Ziihera-based combinations compared with trastuzumab plus chemotherapy in first line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.

Management reported that the overall survival hazard ratio for Ziihera plus chemotherapy, with and without Tevimbra, improved compared with the first interim analysis. The safety profile remained generally consistent with earlier HERIZON-GEA-01 data.

For investors, the combination of confirmed efficacy, the absence of new safety signals and recent U.S. approval provides a new reference point when weighing Jazz Pharmaceuticals’ oncology portfolio against its existing sleep and neurology therapies.

Recent performance reflects that shift in attention. Jazz Pharmaceuticals’ share price has climbed 41.96% year to date to US$245.80, while the 1-year total shareholder return of 94.83% points to strong momentum despite some softer 7 day and 30 day share price moves.

Fresh HERIZON-GEA-01 data and the August Ziihera approval arrived as the firm prepared for a busy investor circuit. Management is set to speak at Wells Fargo’s healthcare conference on 9 September and Citigroup’s biopharma summit on 10 September 2026. These touchpoints give the market more information to reassess Jazz Pharmaceuticals’ growth prospects and risk profile around oncology relative to its established sleep and neurology franchises.

Scan 16 high quality undiscovered gems that, like Jazz Pharmaceuticals after Ziihera’s Phase 3 data, pair late-stage pipelines with underappreciated oncology and specialty therapy potential.

After a near doubling in 12 months and fresh Ziihera data in hand, Jazz Pharmaceuticals now faces a simpler and harder question. Does the current price still leave enough upside to justify the oncology and margin risks?

Most Popular Narrative: 15.1% Undervalued

Analysts’ most followed narrative puts Jazz Pharmaceuticals’ fair value at $289.45, which sits above the recent $245.80 close and frames Ziihera as a key swing factor for future oncology weight in the story.

New product launches and portfolio expansion across neuroscience, rare cancers, and cannabinoid therapies are driving robust topline growth and international market penetration. Strategic acquisitions and ongoing R&D investments are diversifying assets, extending patent protection, and enhancing earnings stability while reducing dependence on legacy products.

Read the complete narrative. Read the complete narrative.

Want to understand why this framework still sees upside after a 1 year total return close to 95%? The narrative leans on compounding earnings, firming margins, and a valuation multiple that assumes Jazz Pharmaceuticals can grow into a larger role in neuroscience and oncology over time. Curious which revenue paths and profitability targets need to line up for that to hold?

Result: Fair Value of $289.45 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

Still, the Jazz Pharmaceuticals story can be knocked off course if patent expiries bite harder than expected or if the broader roll out of Ziihera disappoints.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Next Steps

Mixed signals around Jazz Pharmaceuticals’ oncology potential and patent risk profile make this a judgement call. Move quickly, review the evidence, and weigh the 3 key rewards and 2 important warning signs.

Looking for more Jazz Pharmaceuticals investment ideas?

If Jazz Pharmaceuticals has sharpened your focus on where risk and reward can line up, do not stop here. Broader opportunities often appear where attention has not fully shifted yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com